Immunization and immunotherapy for mastitis.

J. W. Tyler, James S Cullor, D. C. Ruffin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Immunization and immunotherapy for mastitis are active areas of investigation. The past decade has seen development of effective and economical R-mutant vaccines for gram-negative mastitis. These vaccines doubtless will prove beneficial on well managed dairies that have eradicated contagious mastitis pathogens. Development of vaccines for other mastitis pathogens has been noticeably slower. A commercially available Staphylococcus aureus vaccine appears to reduce the frequency and severity of clinical episodes, but probably has minimal impact on the incidence or prevalence of infection. This product has not been extensively studied. The recent recognition of virulence factors produced in vivo by Staphylococcus aureus may provide a breakthrough in the development and production of Staphylococcus aureus vaccines. Bacterins employing this principle presently are not commercially available, however. In the case of all contagious mastitis pathogens (Streptococcus agalactiae, Staphylococcus aureus, and Mycoplasma spp.), traditional control and eradication efforts (teat dip, dry cow therapy, culling programs) likely will prove preferable to long-term immunization. Ongoing research may provide more efficacious vaccines for these mastitis syndromes. Immunostimulants are an active area of research. Although leukopoietic factors appear promising as immunostimulants, no compound has clearly demonstrated efficacy in either the prevention or treatment of bovine mastitis.

Original languageEnglish (US)
Pages (from-to)537-549
Number of pages13
JournalThe Veterinary clinics of North America. Food animal practice
Volume9
Issue number3
StatePublished - Nov 1993
Externally publishedYes

Fingerprint

Mastitis
immunotherapy
Immunotherapy
mastitis
Immunization
immunization
Vaccines
Staphylococcus aureus
vaccines
Immunologic Adjuvants
immunostimulants
pathogens
Bovine Mastitis
Bacterial Vaccines
Active Immunotherapy
Streptococcus agalactiae
bovine mastitis
Mycoplasma
vaccine development
Virulence Factors

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Immunization and immunotherapy for mastitis. / Tyler, J. W.; Cullor, James S; Ruffin, D. C.

In: The Veterinary clinics of North America. Food animal practice, Vol. 9, No. 3, 11.1993, p. 537-549.

Research output: Contribution to journalArticle

@article{751ffd5a4acd491692ed109f014e7c11,
title = "Immunization and immunotherapy for mastitis.",
abstract = "Immunization and immunotherapy for mastitis are active areas of investigation. The past decade has seen development of effective and economical R-mutant vaccines for gram-negative mastitis. These vaccines doubtless will prove beneficial on well managed dairies that have eradicated contagious mastitis pathogens. Development of vaccines for other mastitis pathogens has been noticeably slower. A commercially available Staphylococcus aureus vaccine appears to reduce the frequency and severity of clinical episodes, but probably has minimal impact on the incidence or prevalence of infection. This product has not been extensively studied. The recent recognition of virulence factors produced in vivo by Staphylococcus aureus may provide a breakthrough in the development and production of Staphylococcus aureus vaccines. Bacterins employing this principle presently are not commercially available, however. In the case of all contagious mastitis pathogens (Streptococcus agalactiae, Staphylococcus aureus, and Mycoplasma spp.), traditional control and eradication efforts (teat dip, dry cow therapy, culling programs) likely will prove preferable to long-term immunization. Ongoing research may provide more efficacious vaccines for these mastitis syndromes. Immunostimulants are an active area of research. Although leukopoietic factors appear promising as immunostimulants, no compound has clearly demonstrated efficacy in either the prevention or treatment of bovine mastitis.",
author = "Tyler, {J. W.} and Cullor, {James S} and Ruffin, {D. C.}",
year = "1993",
month = "11",
language = "English (US)",
volume = "9",
pages = "537--549",
journal = "Veterinary Clinics of North America - Food Animal Practice",
issn = "0749-0720",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Immunization and immunotherapy for mastitis.

AU - Tyler, J. W.

AU - Cullor, James S

AU - Ruffin, D. C.

PY - 1993/11

Y1 - 1993/11

N2 - Immunization and immunotherapy for mastitis are active areas of investigation. The past decade has seen development of effective and economical R-mutant vaccines for gram-negative mastitis. These vaccines doubtless will prove beneficial on well managed dairies that have eradicated contagious mastitis pathogens. Development of vaccines for other mastitis pathogens has been noticeably slower. A commercially available Staphylococcus aureus vaccine appears to reduce the frequency and severity of clinical episodes, but probably has minimal impact on the incidence or prevalence of infection. This product has not been extensively studied. The recent recognition of virulence factors produced in vivo by Staphylococcus aureus may provide a breakthrough in the development and production of Staphylococcus aureus vaccines. Bacterins employing this principle presently are not commercially available, however. In the case of all contagious mastitis pathogens (Streptococcus agalactiae, Staphylococcus aureus, and Mycoplasma spp.), traditional control and eradication efforts (teat dip, dry cow therapy, culling programs) likely will prove preferable to long-term immunization. Ongoing research may provide more efficacious vaccines for these mastitis syndromes. Immunostimulants are an active area of research. Although leukopoietic factors appear promising as immunostimulants, no compound has clearly demonstrated efficacy in either the prevention or treatment of bovine mastitis.

AB - Immunization and immunotherapy for mastitis are active areas of investigation. The past decade has seen development of effective and economical R-mutant vaccines for gram-negative mastitis. These vaccines doubtless will prove beneficial on well managed dairies that have eradicated contagious mastitis pathogens. Development of vaccines for other mastitis pathogens has been noticeably slower. A commercially available Staphylococcus aureus vaccine appears to reduce the frequency and severity of clinical episodes, but probably has minimal impact on the incidence or prevalence of infection. This product has not been extensively studied. The recent recognition of virulence factors produced in vivo by Staphylococcus aureus may provide a breakthrough in the development and production of Staphylococcus aureus vaccines. Bacterins employing this principle presently are not commercially available, however. In the case of all contagious mastitis pathogens (Streptococcus agalactiae, Staphylococcus aureus, and Mycoplasma spp.), traditional control and eradication efforts (teat dip, dry cow therapy, culling programs) likely will prove preferable to long-term immunization. Ongoing research may provide more efficacious vaccines for these mastitis syndromes. Immunostimulants are an active area of research. Although leukopoietic factors appear promising as immunostimulants, no compound has clearly demonstrated efficacy in either the prevention or treatment of bovine mastitis.

UR - http://www.scopus.com/inward/record.url?scp=0027691078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027691078&partnerID=8YFLogxK

M3 - Article

C2 - 8242458

AN - SCOPUS:0027691078

VL - 9

SP - 537

EP - 549

JO - Veterinary Clinics of North America - Food Animal Practice

JF - Veterinary Clinics of North America - Food Animal Practice

SN - 0749-0720

IS - 3

ER -